August 28, 2023 11:39 AM EDTUpdated 11:59 AM
R&D

Am­gen says RNA heart drug has long-last­ing ef­fect as it races No­var­tis; Eli Lil­ly takes pill ap­proach to same tar­get: #ESC23

Lei Lei Wu

News Reporter

Am­gen and Eli Lil­ly un­veiled new da­ta for their ex­per­i­men­tal heart drugs that tar­get lipopro­tein(a) — a cho­les­terol car­ri­er that can in­crease the risk of heart …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times